English

Mirum Pharmaceuticals, Inc.

EDGAR

MIRM Current report (8-K) · filed 2026-10-26

Annual consolidated revenue for 2025: about USD 521.3M, using the latest reported figures. The previous period, 2024, was about USD 336.9M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

176 million USD

2026 Q2 · USD

Exact inputs and evidence

Revenue: 176243000 USD Source

Operating margin

-24.14%

2026 Q2 · %

Exact inputs and evidence

Operating Income: -42537000 USD Source
Revenue: 176243000 USD Source

Operating cash flow

-44.3 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -273015000 USD Source
Operating Cash Flow: -228763000 USD Source

Free cash flow

-44.3 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -273015000 USD Source
Operating Cash Flow: -228763000 USD Source
Capital Expenditure: 687000 USD Source
Capital Expenditure: 664000 USD Source

Cash and cash equivalents: 331 million USD 2026-06-30 Source
Exact value

330728000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 64.8 million shares 2026-06-30 Source
Exact value

64754699 shares

Reported share-count change

29.36% · 14.7 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

50058392 shares · 2025-06-30· Source
64754699 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

618 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Revenue: 133010000 USD · 2025-07-01 – 2025-09-30 Source
Revenue: 521312000 USD · 2025-01-01 – 2025-12-31 Source
Revenue: 372380000 USD · 2025-01-01 – 2025-09-30 Source
Revenue: 159882000 USD · 2026-01-01 – 2026-03-31 Source
Revenue: 176243000 USD · 2026-04-01 – 2026-06-30 Source

Net income

-860 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: 2905000 USD · 2025-07-01 – 2025-09-30 Source
Net income: -23363000 USD · 2025-01-01 – 2025-12-31 Source
Net income: -17633000 USD · 2025-01-01 – 2025-09-30 Source
Net income: -790155000 USD · 2026-01-01 – 2026-03-31 Source
Net income: -67227000 USD · 2026-04-01 – 2026-06-30 Source

Operating cash flow

-227 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: 49760000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: 10079000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: 55827000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: 49760000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -228763000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -273015000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -228763000 USD · 2026-01-01 – 2026-03-31 Source

Capital expenditure

1.47 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Capital expenditure: 354000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 167000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 954000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 354000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 664000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 687000 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 664000 USD · 2026-01-01 – 2026-03-31 Source

Free cash flow

-229 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: 49760000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: 10079000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: 55827000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: 49760000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -228763000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -273015000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -228763000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 354000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 167000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 954000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 354000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 664000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 687000 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 664000 USD · 2026-01-01 – 2026-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-10-26.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 6 of 11 periods available· newest 2025-12-31
Operating income: 7 of 11 periods available· newest 2025-12-31
Net income: 7 of 11 periods available· newest 2025-12-31
Operating cash flow: 7 of 11 periods available· newest 2025-12-31
Capital expenditure: 7 of 11 periods available· newest 2025-12-31
Total assets: 6 of 11 periods available· newest 2025-12-31
Total liabilities: 6 of 11 periods available· newest 2025-12-31
Current assets: 6 of 11 periods available· newest 2025-12-31
Current liabilities: 6 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 6 of 11 periods available· newest 2025-12-31
long term debt: No compatible figures in this window
Shares outstanding: 6 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+54.7%

Prior period

USD 336.89 million

2024-01-01 – 2024-12-31
Current period

USD 521.31 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

521312000 − 336888000 = 184424000 USD

336888000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
521312000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Mirum Pharmaceuticals, Inc. · 2025-12-31 Mirum Pharmaceuticals, Inc. (edgar:1759425) Year-over-year change in Revenue: 184424000 USD Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T13:38:45Z Snapshot: adc86e137c1d5c1728af1c8dd6f7a4365ff3883d721ec927eeb3c935682b348d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1759425?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 521312000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1759425/000175942526000013/mirm-20251231.htm#1581875 Filing: 000175942526000013 Input fundies:Revenue: 336888000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1759425/000175942526000013/mirm-20251231.htm#1582850 Filing: 000175942526000013
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 64.58 million

Prior period

−USD 87.94 million

2024-01-01 – 2024-12-31
Current period

−USD 23.36 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-23363000 − -87942000 = 64579000 USD

-87942000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-23363000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Mirum Pharmaceuticals, Inc. · 2025-12-31 Mirum Pharmaceuticals, Inc. (edgar:1759425) Year-over-year change in Net income: 64579000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T13:38:45Z Snapshot: adc86e137c1d5c1728af1c8dd6f7a4365ff3883d721ec927eeb3c935682b348d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1759425?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -23363000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1759425/000175942526000013/mirm-20251231.htm#1394170 Filing: 000175942526000013 Input fundies:NetIncome: -87942000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1759425/000175942526000013/mirm-20251231.htm#1370472 Filing: 000175942526000013
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+440.7%

Prior period

USD 10.33 million

2024-01-01 – 2024-12-31
Current period

USD 55.83 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

55827000 − 10325000 = 45502000 USD

10325000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
55827000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Mirum Pharmaceuticals, Inc. · 2025-12-31 Mirum Pharmaceuticals, Inc. (edgar:1759425) Year-over-year change in Operating cash flow: 45502000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T13:38:45Z Snapshot: adc86e137c1d5c1728af1c8dd6f7a4365ff3883d721ec927eeb3c935682b348d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1759425?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: 55827000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1759425/000175942526000013/mirm-20251231.htm#1442630 Filing: 000175942526000013 Input fundies:OperatingCashFlow: 10325000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1759425/000175942526000013/mirm-20251231.htm#1443284 Filing: 000175942526000013
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-3.9%

Prior period

USD 993,000

2024-01-01 – 2024-12-31
Current period

USD 954,000

2025-01-01 – 2025-12-31

Exact inputs and evidence

954000 − 993000 = -39000 USD

993000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
954000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Mirum Pharmaceuticals, Inc. · 2025-12-31 Mirum Pharmaceuticals, Inc. (edgar:1759425) Year-over-year change in Capital expenditure: -39000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T13:38:45Z Snapshot: adc86e137c1d5c1728af1c8dd6f7a4365ff3883d721ec927eeb3c935682b348d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1759425?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 954000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1759425/000175942526000013/mirm-20251231.htm#1449515 Filing: 000175942526000013 Input fundies:CapitalExpenditure: 993000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1759425/000175942526000013/mirm-20251231.htm#1450075 Filing: 000175942526000013
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue USD 521.31 million 100% of revenue
Operating costs Derived USD 543.45 million 104% of revenue
Operating income −USD 22.14 million −4.2% of revenue
Tax, interest and other Derived USD 1.23 million 0.2% of revenue
Net income −USD 23.36 million −4.5% of revenue

Cash

Operating cash flow USD 55.83 million 11% of revenue
Capital expenditure USD 954,000 0.2% of revenue
Free cash flow Derived USD 54.87 million 11% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2020 Not shown: operating income or net income is not reported.
2021 Operating loss: operating costs were 1,006% of revenue.
2022 Operating loss: operating costs were 270% of revenue.
2023 Operating loss: operating costs were 159% of revenue.
2024 Operating loss: operating costs were 126% of revenue.
2025 Operating loss: operating costs were 104% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2020 2020-01-01 – 2020-12-31	0	104296000 Derived	-104296000	-1026000 Derived	-103270000	-89300000 Derived	Source 2020-01-01 – 2020-12-31: 0 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -104296000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -103270000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -89075000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 225000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	19138000	192551000 Derived	-173413000	-89425000 Derived	-83988000	-132782000 Derived	Source 2021-01-01 – 2021-12-31: 19138000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -173413000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -83988000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -132758000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 24000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	77062000	208282000 Derived	-131220000	4445000 Derived	-135665000	-120414000 Derived	Source 2022-01-01 – 2022-12-31: 77062000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -131220000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -135665000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -120136000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 278000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	186374000	295528000 Derived	-109154000	54261000 Derived	-163415000	-71053000 Derived	Source 2023-01-01 – 2023-12-31: 186374000 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -109154000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -163415000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -70944000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 109000 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	336888000	424494000 Derived	-87606000	336000 Derived	-87942000	9332000 Derived	Source 2024-01-01 – 2024-12-31: 336888000 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -87606000 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -87942000 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: 10325000 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 993000 USD Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	521312000	543448000 Derived	-22136000	1227000 Derived	-23363000	54873000 Derived	Source 2025-01-01 – 2025-12-31: 521312000 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: -22136000 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -23363000 USD Inspect Net Income Open source 2025-01-01 – 2025-12-31: 55827000 USD Inspect Operating Cash Flow Open source 2025-01-01 – 2025-12-31: 954000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 521.3M 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20202020-12-31	Revenue	0	Revenue: 0 Open source
20212021-12-31	Revenue	19138000	Revenue: 19138000 Open source
20222022-12-31	Revenue	77062000	Revenue: 77062000 Open source
20232023-12-31	Revenue	186374000	Revenue: 186374000 Open source
20242024-12-31	Revenue	336888000	Revenue: 336888000 Open source
20252025-12-31	Revenue	521312000	Revenue: 521312000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

54.7% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Year over year	No prior comparable period	Revenue: 0 Open source
20212021-12-31	Year over year	No prior comparable period	Revenue: 19138000 Open source Revenue: 0 Open source
20222022-12-31	Year over year	302.7%	Revenue: 77062000 Open source Revenue: 19138000 Open source
20232023-12-31	Year over year	141.8%	Revenue: 186374000 Open source Revenue: 77062000 Open source
20242024-12-31	Year over year	80.8%	Revenue: 336888000 Open source Revenue: 186374000 Open source
20252025-12-31	Year over year	54.7%	Revenue: 521312000 Open source Revenue: 336888000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -4.2% 2025

Net margin -4.5% 2025

Free cash flow margin 10.5% 2025

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Operating margin	Not reported	Operating Income: -104296000 Open source Revenue: 0 Open source
20212021-12-31	Operating margin	-906.1%	Operating Income: -173413000 Open source Revenue: 19138000 Open source
20222022-12-31	Operating margin	-170.3%	Operating Income: -131220000 Open source Revenue: 77062000 Open source
20232023-12-31	Operating margin	-58.6%	Operating Income: -109154000 Open source Revenue: 186374000 Open source
20242024-12-31	Operating margin	-26%	Operating Income: -87606000 Open source Revenue: 336888000 Open source
20252025-12-31	Operating margin	-4.2%	Operating Income: -22136000 Open source Revenue: 521312000 Open source
20202020-12-31	Net margin	Not reported	Net Income: -103270000 Open source Revenue: 0 Open source
20212021-12-31	Net margin	-438.9%	Net Income: -83988000 Open source Revenue: 19138000 Open source
20222022-12-31	Net margin	-176%	Net Income: -135665000 Open source Revenue: 77062000 Open source
20232023-12-31	Net margin	-87.7%	Net Income: -163415000 Open source Revenue: 186374000 Open source
20242024-12-31	Net margin	-26.1%	Net Income: -87942000 Open source Revenue: 336888000 Open source
20252025-12-31	Net margin	-4.5%	Net Income: -23363000 Open source Revenue: 521312000 Open source
20202020-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -89075000 Open source Capital Expenditure: 225000 Open source
20212021-12-31	Free cash flow margin	-693.8%	Revenue: 19138000 Open source Operating Cash Flow: -132758000 Open source Capital Expenditure: 24000 Open source
20222022-12-31	Free cash flow margin	-156.3%	Revenue: 77062000 Open source Operating Cash Flow: -120136000 Open source Capital Expenditure: 278000 Open source
20232023-12-31	Free cash flow margin	-38.1%	Revenue: 186374000 Open source Operating Cash Flow: -70944000 Open source Capital Expenditure: 109000 Open source
20242024-12-31	Free cash flow margin	2.8%	Revenue: 336888000 Open source Operating Cash Flow: 10325000 Open source Capital Expenditure: 993000 Open source
20252025-12-31	Free cash flow margin	10.5%	Revenue: 521312000 Open source Operating Cash Flow: 55827000 Open source Capital Expenditure: 954000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD 55.8M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20202020-12-31	Operating cash flow	-89075000	Operating Cash Flow: -89075000 Open source
20212021-12-31	Operating cash flow	-132758000	Operating Cash Flow: -132758000 Open source
20222022-12-31	Operating cash flow	-120136000	Operating Cash Flow: -120136000 Open source
20232023-12-31	Operating cash flow	-70944000	Operating Cash Flow: -70944000 Open source
20242024-12-31	Operating cash flow	10325000	Operating Cash Flow: 10325000 Open source
20252025-12-31	Operating cash flow	55827000	Operating Cash Flow: 55827000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD 54.9M 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20202020-12-31	Free cash flow	-89300000	Operating Cash Flow: -89075000 Open source Capital Expenditure: 225000 Open source
20212021-12-31	Free cash flow	-132782000	Operating Cash Flow: -132758000 Open source Capital Expenditure: 24000 Open source
20222022-12-31	Free cash flow	-120414000	Operating Cash Flow: -120136000 Open source Capital Expenditure: 278000 Open source
20232023-12-31	Free cash flow	-71053000	Operating Cash Flow: -70944000 Open source Capital Expenditure: 109000 Open source
20242024-12-31	Free cash flow	9332000	Operating Cash Flow: 10325000 Open source Capital Expenditure: 993000 Open source
20252025-12-31	Free cash flow	54873000	Operating Cash Flow: 55827000 Open source Capital Expenditure: 954000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

62.7% 2025

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Liabilities / assets	28.6%	Total Liabilities: 68769000 Open source Total Assets: 240864000 Open source
20212021-12-31	Liabilities / assets	59.2%	Total Liabilities: 174439000 Open source Total Assets: 294651000 Open source
20222022-12-31	Liabilities / assets	59.8%	Total Liabilities: 210869000 Open source Total Assets: 352906000 Open source
20232023-12-31	Liabilities / assets	61.5%	Total Liabilities: 397951000 Open source Total Assets: 646621000 Open source
20242024-12-31	Liabilities / assets	66.4%	Total Liabilities: 445114000 Open source Total Assets: 670754000 Open source
20252025-12-31	Liabilities / assets	62.7%	Total Liabilities: 528123000 Open source Total Assets: 842813000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

2.67× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Current assets / current liabilities	12.8×	Current Assets: 236350000 Open source Current Liabilities: 18462000 Open source
20212021-12-31	Current assets / current liabilities	3.91×	Current Assets: 166592000 Open source Current Liabilities: 42596000 Open source
20222022-12-31	Current assets / current liabilities	2.94×	Current Assets: 190225000 Open source Current Liabilities: 64729000 Open source
20232023-12-31	Current assets / current liabilities	4.45×	Current Assets: 387541000 Open source Current Liabilities: 87064000 Open source
20242024-12-31	Current assets / current liabilities	3.1×	Current Assets: 392788000 Open source Current Liabilities: 126551000 Open source
20252025-12-31	Current assets / current liabilities	2.67×	Current Assets: 549684000 Open source Current Liabilities: 205799000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2019 2019-01-01 – 2019-12-31	−USD 52.55 million Exact value Exact value: -52553000 USD 2019-01-01 – 2019-12-31: -52553000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Mirum Pharmaceuticals, Inc. · 2019-12-31 Mirum Pharmaceuticals, Inc. (edgar:1759425) Net Income: -52553000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T13:38:45Z Snapshot: adc86e137c1d5c1728af1c8dd6f7a4365ff3883d721ec927eeb3c935682b348d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1759425/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -52553000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1759425/000156459021011756/mirm-20201231.xml#168436 Filing: 000156459021011756 The citation records this snapshot. The page link may show a newer release later.	−USD 39.36 million Exact value Exact value: -39362000 USD 2019-01-01 – 2019-12-31: -39362000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Mirum Pharmaceuticals, Inc. · 2019-12-31 Mirum Pharmaceuticals, Inc. (edgar:1759425) Operating Cash Flow: -39362000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T13:38:45Z Snapshot: adc86e137c1d5c1728af1c8dd6f7a4365ff3883d721ec927eeb3c935682b348d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1759425/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -39362000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1759425/000156459021011756/mirm-20201231.xml#194999 Filing: 000156459021011756 The citation records this snapshot. The page link may show a newer release later.	USD 281,000 Exact value Exact value: 281000 USD 2019-01-01 – 2019-12-31: 281000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Mirum Pharmaceuticals, Inc. · 2019-12-31 Mirum Pharmaceuticals, Inc. (edgar:1759425) Capital Expenditure: 281000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T13:38:45Z Snapshot: adc86e137c1d5c1728af1c8dd6f7a4365ff3883d721ec927eeb3c935682b348d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1759425/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 281000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1759425/000156459021011756/mirm-20201231.xml#196684 Filing: 000156459021011756 The citation records this snapshot. The page link may show a newer release later.	−USD 39.64 million Calculation and evidence -39362000 − 281000 USD Exact free cash flow: -39643000 USD 2019-01-01 – 2019-12-31: -39362000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 281000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Mirum Pharmaceuticals, Inc. · 2019-12-31 Mirum Pharmaceuticals, Inc. (edgar:1759425) Free cash flow: -39643000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T13:38:45Z Snapshot: adc86e137c1d5c1728af1c8dd6f7a4365ff3883d721ec927eeb3c935682b348d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1759425?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -39362000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1759425/000156459021011756/mirm-20201231.xml#194999 Filing: 000156459021011756 Input fundies:CapitalExpenditure: 281000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1759425/000156459021011756/mirm-20201231.xml#196684 Filing: 000156459021011756 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 103.27 million Exact value Exact value: -103270000 USD 2020-01-01 – 2020-12-31: -103270000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Mirum Pharmaceuticals, Inc. · 2020-12-31 Mirum Pharmaceuticals, Inc. (edgar:1759425) Net Income: -103270000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T13:38:45Z Snapshot: adc86e137c1d5c1728af1c8dd6f7a4365ff3883d721ec927eeb3c935682b348d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1759425/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -103270000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1759425/000095017022003229/mirm-20211231.htm#2094521 Filing: 000095017022003229 The citation records this snapshot. The page link may show a newer release later.	−USD 89.08 million Exact value Exact value: -89075000 USD 2020-01-01 – 2020-12-31: -89075000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Mirum Pharmaceuticals, Inc. · 2020-12-31 Mirum Pharmaceuticals, Inc. (edgar:1759425) Operating Cash Flow: -89075000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T13:38:45Z Snapshot: adc86e137c1d5c1728af1c8dd6f7a4365ff3883d721ec927eeb3c935682b348d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1759425/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -89075000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1759425/000095017022003229/mirm-20211231.htm#2314609 Filing: 000095017022003229 The citation records this snapshot. The page link may show a newer release later.	USD 225,000 Exact value Exact value: 225000 USD 2020-01-01 – 2020-12-31: 225000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Mirum Pharmaceuticals, Inc. · 2020-12-31 Mirum Pharmaceuticals, Inc. (edgar:1759425) Capital Expenditure: 225000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T13:38:45Z Snapshot: adc86e137c1d5c1728af1c8dd6f7a4365ff3883d721ec927eeb3c935682b348d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1759425/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 225000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1759425/000095017022003229/mirm-20211231.htm#2334084 Filing: 000095017022003229 The citation records this snapshot. The page link may show a newer release later.	−USD 89.3 million Calculation and evidence -89075000 − 225000 USD Exact free cash flow: -89300000 USD 2020-01-01 – 2020-12-31: -89075000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 225000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Mirum Pharmaceuticals, Inc. · 2020-12-31 Mirum Pharmaceuticals, Inc. (edgar:1759425) Free cash flow: -89300000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T13:38:45Z Snapshot: adc86e137c1d5c1728af1c8dd6f7a4365ff3883d721ec927eeb3c935682b348d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1759425?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -89075000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1759425/000095017022003229/mirm-20211231.htm#2314609 Filing: 000095017022003229 Input fundies:CapitalExpenditure: 225000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1759425/000095017022003229/mirm-20211231.htm#2334084 Filing: 000095017022003229 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 83.99 million Exact value Exact value: -83988000 USD 2021-01-01 – 2021-12-31: -83988000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Mirum Pharmaceuticals, Inc. · 2021-12-31 Mirum Pharmaceuticals, Inc. (edgar:1759425) Net Income: -83988000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T13:38:45Z Snapshot: adc86e137c1d5c1728af1c8dd6f7a4365ff3883d721ec927eeb3c935682b348d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1759425/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -83988000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1759425/000095017024032289/mirm-20231231.htm#1734985 Filing: 000095017024032289 The citation records this snapshot. The page link may show a newer release later.	−USD 132.76 million Exact value Exact value: -132758000 USD 2021-01-01 – 2021-12-31: -132758000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Mirum Pharmaceuticals, Inc. · 2021-12-31 Mirum Pharmaceuticals, Inc. (edgar:1759425) Operating Cash Flow: -132758000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T13:38:45Z Snapshot: adc86e137c1d5c1728af1c8dd6f7a4365ff3883d721ec927eeb3c935682b348d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1759425/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -132758000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1759425/000095017024032289/mirm-20231231.htm#1993300 Filing: 000095017024032289 The citation records this snapshot. The page link may show a newer release later.	USD 24,000 Exact value Exact value: 24000 USD 2021-01-01 – 2021-12-31: 24000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Mirum Pharmaceuticals, Inc. · 2021-12-31 Mirum Pharmaceuticals, Inc. (edgar:1759425) Capital Expenditure: 24000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T13:38:45Z Snapshot: adc86e137c1d5c1728af1c8dd6f7a4365ff3883d721ec927eeb3c935682b348d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1759425/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 24000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1759425/000095017024032289/mirm-20231231.htm#2012472 Filing: 000095017024032289 The citation records this snapshot. The page link may show a newer release later.	−USD 132.78 million Calculation and evidence -132758000 − 24000 USD Exact free cash flow: -132782000 USD 2021-01-01 – 2021-12-31: -132758000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 24000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Mirum Pharmaceuticals, Inc. · 2021-12-31 Mirum Pharmaceuticals, Inc. (edgar:1759425) Free cash flow: -132782000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T13:38:45Z Snapshot: adc86e137c1d5c1728af1c8dd6f7a4365ff3883d721ec927eeb3c935682b348d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1759425?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -132758000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1759425/000095017024032289/mirm-20231231.htm#1993300 Filing: 000095017024032289 Input fundies:CapitalExpenditure: 24000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1759425/000095017024032289/mirm-20231231.htm#2012472 Filing: 000095017024032289 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 135.67 million Exact value Exact value: -135665000 USD 2022-01-01 – 2022-12-31: -135665000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Mirum Pharmaceuticals, Inc. · 2022-12-31 Mirum Pharmaceuticals, Inc. (edgar:1759425) Net Income: -135665000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T13:38:45Z Snapshot: adc86e137c1d5c1728af1c8dd6f7a4365ff3883d721ec927eeb3c935682b348d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1759425/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -135665000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1759425/000175942525000014/mirm-20241231.htm#1353291 Filing: 000175942525000014 The citation records this snapshot. The page link may show a newer release later.	−USD 120.14 million Exact value Exact value: -120136000 USD 2022-01-01 – 2022-12-31: -120136000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Mirum Pharmaceuticals, Inc. · 2022-12-31 Mirum Pharmaceuticals, Inc. (edgar:1759425) Operating Cash Flow: -120136000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T13:38:45Z Snapshot: adc86e137c1d5c1728af1c8dd6f7a4365ff3883d721ec927eeb3c935682b348d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1759425/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -120136000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1759425/000175942525000014/mirm-20241231.htm#1458192 Filing: 000175942525000014 The citation records this snapshot. The page link may show a newer release later.	USD 278,000 Exact value Exact value: 278000 USD 2022-01-01 – 2022-12-31: 278000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Mirum Pharmaceuticals, Inc. · 2022-12-31 Mirum Pharmaceuticals, Inc. (edgar:1759425) Capital Expenditure: 278000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T13:38:45Z Snapshot: adc86e137c1d5c1728af1c8dd6f7a4365ff3883d721ec927eeb3c935682b348d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1759425/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 278000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1759425/000175942525000014/mirm-20241231.htm#1465056 Filing: 000175942525000014 The citation records this snapshot. The page link may show a newer release later.	−USD 120.41 million Calculation and evidence -120136000 − 278000 USD Exact free cash flow: -120414000 USD 2022-01-01 – 2022-12-31: -120136000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 278000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Mirum Pharmaceuticals, Inc. · 2022-12-31 Mirum Pharmaceuticals, Inc. (edgar:1759425) Free cash flow: -120414000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T13:38:45Z Snapshot: adc86e137c1d5c1728af1c8dd6f7a4365ff3883d721ec927eeb3c935682b348d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1759425?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -120136000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1759425/000175942525000014/mirm-20241231.htm#1458192 Filing: 000175942525000014 Input fundies:CapitalExpenditure: 278000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1759425/000175942525000014/mirm-20241231.htm#1465056 Filing: 000175942525000014 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 163.42 million Exact value Exact value: -163415000 USD 2023-01-01 – 2023-12-31: -163415000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Mirum Pharmaceuticals, Inc. · 2023-12-31 Mirum Pharmaceuticals, Inc. (edgar:1759425) Net Income: -163415000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T13:38:45Z Snapshot: adc86e137c1d5c1728af1c8dd6f7a4365ff3883d721ec927eeb3c935682b348d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1759425/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -163415000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1759425/000175942526000013/mirm-20251231.htm#1349880 Filing: 000175942526000013 The citation records this snapshot. The page link may show a newer release later.	−USD 70.94 million Exact value Exact value: -70944000 USD 2023-01-01 – 2023-12-31: -70944000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Mirum Pharmaceuticals, Inc. · 2023-12-31 Mirum Pharmaceuticals, Inc. (edgar:1759425) Operating Cash Flow: -70944000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T13:38:45Z Snapshot: adc86e137c1d5c1728af1c8dd6f7a4365ff3883d721ec927eeb3c935682b348d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1759425/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -70944000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1759425/000175942526000013/mirm-20251231.htm#1443940 Filing: 000175942526000013 The citation records this snapshot. The page link may show a newer release later.	USD 109,000 Exact value Exact value: 109000 USD 2023-01-01 – 2023-12-31: 109000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Mirum Pharmaceuticals, Inc. · 2023-12-31 Mirum Pharmaceuticals, Inc. (edgar:1759425) Capital Expenditure: 109000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T13:38:45Z Snapshot: adc86e137c1d5c1728af1c8dd6f7a4365ff3883d721ec927eeb3c935682b348d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1759425/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 109000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1759425/000175942526000013/mirm-20251231.htm#1450636 Filing: 000175942526000013 The citation records this snapshot. The page link may show a newer release later.	−USD 71.05 million Calculation and evidence -70944000 − 109000 USD Exact free cash flow: -71053000 USD 2023-01-01 – 2023-12-31: -70944000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 109000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Mirum Pharmaceuticals, Inc. · 2023-12-31 Mirum Pharmaceuticals, Inc. (edgar:1759425) Free cash flow: -71053000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T13:38:45Z Snapshot: adc86e137c1d5c1728af1c8dd6f7a4365ff3883d721ec927eeb3c935682b348d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1759425?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -70944000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1759425/000175942526000013/mirm-20251231.htm#1443940 Filing: 000175942526000013 Input fundies:CapitalExpenditure: 109000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1759425/000175942526000013/mirm-20251231.htm#1450636 Filing: 000175942526000013 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 87.94 million Exact value Exact value: -87942000 USD 2024-01-01 – 2024-12-31: -87942000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Mirum Pharmaceuticals, Inc. · 2024-12-31 Mirum Pharmaceuticals, Inc. (edgar:1759425) Net Income: -87942000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T13:38:45Z Snapshot: adc86e137c1d5c1728af1c8dd6f7a4365ff3883d721ec927eeb3c935682b348d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1759425/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -87942000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1759425/000175942526000013/mirm-20251231.htm#1370472 Filing: 000175942526000013 The citation records this snapshot. The page link may show a newer release later.	USD 10.33 million Exact value Exact value: 10325000 USD 2024-01-01 – 2024-12-31: 10325000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Mirum Pharmaceuticals, Inc. · 2024-12-31 Mirum Pharmaceuticals, Inc. (edgar:1759425) Operating Cash Flow: 10325000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T13:38:45Z Snapshot: adc86e137c1d5c1728af1c8dd6f7a4365ff3883d721ec927eeb3c935682b348d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1759425/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 10325000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1759425/000175942526000013/mirm-20251231.htm#1443284 Filing: 000175942526000013 The citation records this snapshot. The page link may show a newer release later.	USD 993,000 Exact value Exact value: 993000 USD 2024-01-01 – 2024-12-31: 993000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Mirum Pharmaceuticals, Inc. · 2024-12-31 Mirum Pharmaceuticals, Inc. (edgar:1759425) Capital Expenditure: 993000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T13:38:45Z Snapshot: adc86e137c1d5c1728af1c8dd6f7a4365ff3883d721ec927eeb3c935682b348d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1759425/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 993000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1759425/000175942526000013/mirm-20251231.htm#1450075 Filing: 000175942526000013 The citation records this snapshot. The page link may show a newer release later.	USD 9.33 million Calculation and evidence 10325000 − 993000 USD Exact free cash flow: 9332000 USD 2024-01-01 – 2024-12-31: 10325000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 993000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Mirum Pharmaceuticals, Inc. · 2024-12-31 Mirum Pharmaceuticals, Inc. (edgar:1759425) Free cash flow: 9332000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T13:38:45Z Snapshot: adc86e137c1d5c1728af1c8dd6f7a4365ff3883d721ec927eeb3c935682b348d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1759425?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 10325000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1759425/000175942526000013/mirm-20251231.htm#1443284 Filing: 000175942526000013 Input fundies:CapitalExpenditure: 993000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1759425/000175942526000013/mirm-20251231.htm#1450075 Filing: 000175942526000013 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 23.36 million Exact value Exact value: -23363000 USD 2025-01-01 – 2025-12-31: -23363000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Mirum Pharmaceuticals, Inc. · 2025-12-31 Mirum Pharmaceuticals, Inc. (edgar:1759425) Net Income: -23363000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T13:38:45Z Snapshot: adc86e137c1d5c1728af1c8dd6f7a4365ff3883d721ec927eeb3c935682b348d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1759425/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -23363000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1759425/000175942526000013/mirm-20251231.htm#1394170 Filing: 000175942526000013 The citation records this snapshot. The page link may show a newer release later.	USD 55.83 million Exact value Exact value: 55827000 USD 2025-01-01 – 2025-12-31: 55827000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Mirum Pharmaceuticals, Inc. · 2025-12-31 Mirum Pharmaceuticals, Inc. (edgar:1759425) Operating Cash Flow: 55827000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T13:38:45Z Snapshot: adc86e137c1d5c1728af1c8dd6f7a4365ff3883d721ec927eeb3c935682b348d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1759425/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 55827000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1759425/000175942526000013/mirm-20251231.htm#1442630 Filing: 000175942526000013 The citation records this snapshot. The page link may show a newer release later.	USD 954,000 Exact value Exact value: 954000 USD 2025-01-01 – 2025-12-31: 954000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Mirum Pharmaceuticals, Inc. · 2025-12-31 Mirum Pharmaceuticals, Inc. (edgar:1759425) Capital Expenditure: 954000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T13:38:45Z Snapshot: adc86e137c1d5c1728af1c8dd6f7a4365ff3883d721ec927eeb3c935682b348d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1759425/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 954000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1759425/000175942526000013/mirm-20251231.htm#1449515 Filing: 000175942526000013 The citation records this snapshot. The page link may show a newer release later.	USD 54.87 million Calculation and evidence 55827000 − 954000 USD Exact free cash flow: 54873000 USD 2025-01-01 – 2025-12-31: 55827000 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 954000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Mirum Pharmaceuticals, Inc. · 2025-12-31 Mirum Pharmaceuticals, Inc. (edgar:1759425) Free cash flow: 54873000 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T13:38:45Z Snapshot: adc86e137c1d5c1728af1c8dd6f7a4365ff3883d721ec927eeb3c935682b348d Dimensions: Consolidated View: https://fundies.io/companies/edgar/1759425?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 55827000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1759425/000175942526000013/mirm-20251231.htm#1442630 Filing: 000175942526000013 Input fundies:CapitalExpenditure: 954000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1759425/000175942526000013/mirm-20251231.htm#1449515 Filing: 000175942526000013 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

38 filings · 2,298 latest values · 2,298 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001759425, 1759425, MIRM, edgar:1759425

Also known as Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals, Inc.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation